Revelation Biosciences (REVB) Competitors $4.26 -0.14 (-3.16%) Closing price 02/21/2025 03:55 PM EasternExtended Trading$4.12 -0.15 (-3.43%) As of 02/21/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends REVB vs. SYRS, ATNF, ARTL, GRI, PLRZ, BPTH, SNOA, GNPX, PPBT, and SNPXShould you be buying Revelation Biosciences stock or one of its competitors? The main competitors of Revelation Biosciences include Syros Pharmaceuticals (SYRS), 180 Life Sciences (ATNF), Artelo Biosciences (ARTL), GRI Bio (GRI), Polyrizon (PLRZ), Bio-Path (BPTH), Sonoma Pharmaceuticals (SNOA), Genprex (GNPX), Purple Biotech (PPBT), and Synaptogenix (SNPX). These companies are all part of the "pharmaceutical products" industry. Revelation Biosciences vs. Syros Pharmaceuticals 180 Life Sciences Artelo Biosciences GRI Bio Polyrizon Bio-Path Sonoma Pharmaceuticals Genprex Purple Biotech Synaptogenix Revelation Biosciences (NASDAQ:REVB) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, community ranking, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings. Does the MarketBeat Community favor REVB or SYRS? Syros Pharmaceuticals received 337 more outperform votes than Revelation Biosciences when rated by MarketBeat users. However, 63.83% of users gave Revelation Biosciences an outperform vote while only 62.20% of users gave Syros Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRevelation BiosciencesOutperform Votes3063.83% Underperform Votes1736.17% Syros PharmaceuticalsOutperform Votes36762.20% Underperform Votes22337.80% Do institutionals & insiders have more ownership in REVB or SYRS? 12.8% of Revelation Biosciences shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 0.1% of Revelation Biosciences shares are owned by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has better earnings and valuation, REVB or SYRS? Revelation Biosciences has higher earnings, but lower revenue than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRevelation BiosciencesN/AN/A-$120K-$268.16-0.02Syros Pharmaceuticals$9.94M0.47-$164.57M-$3.03-0.06 Do analysts recommend REVB or SYRS? Syros Pharmaceuticals has a consensus price target of $3.33, indicating a potential upside of 1,812.41%. Given Syros Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Syros Pharmaceuticals is more favorable than Revelation Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revelation Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Syros Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the media prefer REVB or SYRS? In the previous week, Syros Pharmaceuticals had 1 more articles in the media than Revelation Biosciences. MarketBeat recorded 1 mentions for Syros Pharmaceuticals and 0 mentions for Revelation Biosciences. Revelation Biosciences' average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score. Company Overall Sentiment Revelation Biosciences Neutral Syros Pharmaceuticals Neutral Which has more volatility and risk, REVB or SYRS? Revelation Biosciences has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Is REVB or SYRS more profitable? Revelation Biosciences' return on equity of -193.51% beat Syros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Revelation BiosciencesN/A -193.51% -84.00% Syros Pharmaceuticals N/A -3,369.56%-97.04% SummarySyros Pharmaceuticals beats Revelation Biosciences on 10 of the 15 factors compared between the two stocks. Get Revelation Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for REVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REVB vs. The Competition Export to ExcelMetricRevelation BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.15M$7.05B$5.80B$8.95BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-0.026.1126.4518.81Price / SalesN/A313.84450.0676.66Price / CashN/A67.8344.0437.47Price / Book0.016.747.634.64Net Income-$120,000.00$138.11M$3.18B$245.69M7 Day Performance-0.44%-2.04%-1.85%-2.63%1 Month Performance-35.50%-1.57%0.19%-2.37%1 Year Performance-91.55%-3.19%17.21%13.64% Revelation Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REVBRevelation Biosciences0.1596 of 5 stars$4.26-3.2%N/A-91.5%$1.15MN/A-0.0210Gap DownSYRSSyros Pharmaceuticals4.243 of 5 stars$0.17-3.2%$3.33+1,890.0%-97.5%$4.49M$386,000.00-0.06120ATNF180 Life SciencesN/A$1.38-1.4%N/A-65.6%$4.39MN/A0.007Analyst ForecastNews CoveragePositive NewsARTLArtelo Biosciences3.1843 of 5 stars$1.35+1.5%$5.50+307.4%-27.5%$4.36MN/A-0.475News CoverageGap DownGRIGRI Bio2.3672 of 5 stars$0.48+0.4%$11.50+2,290.9%-96.7%$4.30MN/A0.001Stock SplitNews CoveragePLRZPolyrizonN/A$1.02-8.9%N/AN/A$4.27MN/A0.00N/AGap DownBPTHBio-Path2.4742 of 5 stars$0.74-5.8%$20.00+2,617.4%-97.9%$4.25MN/A0.0010Analyst ForecastSNOASonoma Pharmaceuticals0.201 of 5 stars$2.61-1.9%N/A+1,447.9%$4.22M$13.97M-0.65180Negative NewsGNPXGenprex4.4819 of 5 stars$0.49+2.0%$10.00+1,929.6%-91.2%$4.19MN/A0.0020Gap DownPPBTPurple Biotech2.4514 of 5 stars$3.11+3.7%$33.00+961.1%N/A$4.14MN/A-0.3520Gap DownSNPXSynaptogenix1.9617 of 5 stars$2.93-5.5%$14.00+377.8%-55.4%$3.99MN/A0.004Gap Up Related Companies and Tools Related Companies Syros Pharmaceuticals Competitors 180 Life Sciences Competitors Artelo Biosciences Competitors GRI Bio Competitors Polyrizon Competitors Bio-Path Competitors Sonoma Pharmaceuticals Competitors Genprex Competitors Purple Biotech Competitors Synaptogenix Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:REVB) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revelation Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revelation Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free REVB Stock Alerts